Clinical Trial Update: Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update showing six-year persistence of immune response after a single dose of the 9-valent HPV vaccine in male and female students.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Cervical Cancer
• Genital Warts
• Human Papillomavirus Infection
• Oropharyngeal Cancer

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Canadian Immunization Research Network | Conditions: HPV Vaccine | Phase 4 | Status: RECRUITING